Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer (vol 5, e225394, 2022)

被引：1
|
作者：
Graf, R. P.
Fisher, V
Weberpals, J.
机构：
来源：
JAMA NETWORK OPEN | 2022年 / 5卷 / 05期
关键词：
D O I：
10.1001/jamanetworkopen.2022.13901
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Oncological Response and Predictive Biomarkers for the Checkpoint Inhibitors in Castration-Resistant Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis
    Fahmy, Omar
    Alhakamy, Nabil A.
    Khairul-Asri, Mohd G.
    Ahmed, Osama A. A.
    Fahmy, Usama A.
    Fresta, Claudia G.
    Caruso, Giuseppe
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (01):
  • [32] COST-EFFECTIVENESS ANALYSIS OF ENZALUTAMIDE FOR PATIENTS WITH CHEMOTHERAPY-NAIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN JAPAN
    Okumura, H.
    Inoue, S.
    Naidoo, S.
    Holmstrom, S.
    Akaza, H.
    VALUE IN HEALTH, 2017, 20 (05) : A107 - A107
  • [33] A prospective, multicenter study on the clinical effectiveness of abiraterone in metastatic castration-resistant prostate cancer in Korea: Pre- vs. post-chemotherapy
    Jeong, Seung-hwan
    Yeon, Sang Eun
    Kim, Su Youn
    Kwon, Tae Gyun
    Jeon, Seong Soo
    Choi, Young Deuk
    Kwon, Dongdeuk
    Ha Chung, Byung
    Hong, Sung-Hoo
    Kim, Byung Hoon
    Lee, Hyo Jin
    Shin, Sang Joon
    Choi, Woo Suk
    Park, Sung Woo
    Kang, Taek Won
    Yun, Seok Joong
    Cho, Jin Seon
    Choi, See Min
    Lee, Na-Ri
    Kwak, Cheol
    INVESTIGATIVE AND CLINICAL UROLOGY, 2023, 64 (05) : 466 - 473
  • [34] Blood-based tumor mutational burden from circulating tumor DNA and immune checkpoint inhibitors in advanced prostate cancer.
    Rauterkus, Grant
    Hadadi, Agreen
    Barnett, Reagan
    Weipert, Caroline
    Drusbosky, Leylah
    Gao, Xin
    Lilly, Michael B.
    Bryce, Alan Haruo
    Naqvi, Syed Arsalan Ahmed
    Barata, Pedro C.
    Bilen, Mehmet Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [35] Nomogram-based prognostic model construction for progression to castration-resistant prostate cancer in patients with high tumor burden and osseous metastatic prostate cancer
    Huang, Yiheng
    Yuan, Dan
    Zeng, Rongfeng
    Wan, Fugui
    Tang, Yubo
    Dong, Yong
    Liu, Xiaorui
    Linghu, Xitao
    Wang, Bin
    Pan, Jiangang
    Liang, Fei
    Huang, Shuai
    AMERICAN JOURNAL OF CANCER RESEARCH, 2024, 14 (09): : 4459 - 4471
  • [36] Fatty acid binding protein 5 inhibitors as novel anticancer agents against metastatic castration-resistant prostate cancer
    Wang, Hehe
    Zhu, Chuanzhou
    Swamynathan, Manojit M.
    Rajput, Shubhra
    Jayanetti, Kalani
    Rendina, Dominick
    Takemura, Kathryn
    Bogdan, Diane
    Wang, Liqun
    Rizzo, Robert C.
    Kaczocha, Martin
    Trotman, Lloyd C.
    Bialkowska, Agnieszka B.
    Ojima, Iwao
    BIOORGANIC & MEDICINAL CHEMISTRY, 2025, 122
  • [37] Efficacy and safety of PARP inhibitors (PARPi) with immune checkpoint inhibitors (ICI) in metastatic castration-resistant prostate cancer (mCRPC): A systematic review and single-arm meta-analysis
    Gazzoni, Gabriela
    Oliveira, Joao Pedro
    Abrahao Reis, Pedro Cotta
    Bittar, Vinicius
    Carvalho, Bruno Murad
    Vilbert, Maysa
    Stecca, Carlos Eduardo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] The Role of Microsatellite Instability/DNA Mismatch Repair Deficiency and Tumor Mutational Burden as Biomarkers in Predicting Response to Immunotherapy in Castration-resistant Prostate Cancer
    Kluemper, Niklas
    Gruenwald, Viktor
    Hartmann, Arndt
    Hoelzel, Michael
    Eckstein, Markus
    EUROPEAN UROLOGY, 2024, 86 (05) : 388 - 390
  • [39] The Role of Microsatellite Instability/DNA Mismatch Repair Deficiency and Tumor Mutational Burden as Biomarkers in Predicting Response to Immunotherapy in Castration-resistant Prostate Cancer
    Kluemper, Niklas
    Eckstein, Markus
    EUROPEAN UROLOGY, 2025, 87 (01) : e17 - e18
  • [40] Circulating tumor DNA (ctDNA) burden and actionable mutations in treatment-na ve metastatic castration-resistant prostate cancer (mCRPC).
    Wyatt, Alexander William
    Annala, Matti
    Parimi, Sunil
    Zulfiqar, Muhammad
    Finch, Daygen L.
    Oja, Conrad D.
    Vergidis, Joanna
    Azad, Arun
    Gleave, Martin
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345